Atherosclerosis: Pathophysiology and Lipid Risk
Atherosclerosis (chronic inflammatory disease of large/medium arteries; initiated by endothelial dysfunction → subintimal LDL accumulation → oxidation → foam cell formation → fatty streak → fibrous plaque → vulnerable plaque → rupture → ACS/stroke): LDL-C (low-density lipoprotein cholesterol; ApoB100-containing; enters subintima when endothelium activated (ICAM-1/VCAM-1 ↑); oxidised by ROS/MPO/15-LOX → oxLDL; recognised by SR-A/SRA1 and CD36 (scavenger receptors on macrophages); scavenger receptor → unregulated cholesterol ester uptake → foam cells (macrophages engorged with CE droplets) → necrotic core of atherosclerotic plaque); HDL-C (ApoA1-containing; reverse cholesterol transport (RCT): ABCA1/ABCG1 → cholesterol efflux from macrophage → ApoA1 → HDL → liver → bile/faecal excretion; SR-BI hepatic HDL uptake; low HDL independent CVD risk factor); TG/VLDL (ApoB100/ApoC-II; hypertriglyceridaemia → VLDL → IDL → small dense LDL (sdLDL; more atherogenic; enters intima more readily; more easily oxidised)). Plaque biology: smooth muscle cell (SMC) migration → fibrous cap; macrophage foam cells → necrotic core; thin fibrous cap + large necrotic core = vulnerable plaque; MMP-9 (macrophage) → fibrous cap degradation → rupture; platelets → thrombus → occlusion.
Spirulina Mechanisms in Cardiovascular Risk Reduction
LDL Oxidation Prevention and Foam Cell Suppression
LDL oxidation (β-carotene/lycopene/zeaxanthin in LDL particle; these antioxidant lipid components provide intra-particle antioxidant protection; spirulina phytonutrients elevate plasma antioxidants that associate with LDL): (1) Carotenoid enrichment of LDL particle (spirulina β-carotene/zeaxanthin/cryptoxanthin → plasma carotenoids +20–35% → LDL-associated carotenoids +15–25% → delayed LDL oxidation lag time +20–30%); (2) Nrf2-glutathione/SOD/catalase (LDL oxidation requires extracellular ROS from endothelial/macrophage NADPH oxidase + intracellular LOOH propagation; Nrf2 → GSH/GPx4 prevents LOOH chain propagation → oxLDL −15–25%); (3) Foam cell: oxLDL → LOX-1 on macrophage/endothelium → NF-κB → SR-A (SRA1; NF-κB target; scavenger receptor upregulated by oxLDL); spirulina NF-κB −30–45% → SR-A −20–30% transcription; (4) ABCA1 (cholesterol efflux transporter; LXR target; PPARγ/α activates LXR → ABCA1 → CE → ApoA1 → HDL; spirulina PPARγ/α partial agonism → ABCA1 +10–20% → cholesterol efflux from foam cells). Net: foam cell CE accumulation −20–30%.
Triglyceride/VLDL Clearance and HDL Enhancement
Plasma TG (VLDL-TG; liver ApoB100 assembly; MTTP (MTP; microsomal TG transfer protein) → VLDL assembly; LPL (lipoprotein lipase; endothelial surface; activated by ApoC-II; inhibited by ApoC-III) → VLDL → IDL → LDL; hepatic lipase → IDL → LDL; TG >1.7 mmol/L: independent CVD risk; sdLDL formation) is reduced by spirulina through: (1) PPARα activation (GLA/EPA spirulina → PPARα → ACOX1/CPT1α/ApoCIII → VLDL-TG catabolism +20–30%; ApoC-III −10–20% → LPL activity +10–20%); (2) AMPK → ACC Ser79 → malonyl-CoA ↓ → FA oxidation ↑ → hepatic FA substrate for VLDL-TG ↓; (3) Omega-3 GLA (1,100 mg/100g GLA; EPA from ALA elongation) → TG-lowering (EPA direct LPL/VLDL mechanism). Plasma TG: −15–25% at 8–12 weeks. HDL (ApoA1; LCAT (lecithin-cholesterol acyltransferase; esterifies free cholesterol on HDL); PPARα → ApoA1 transcription +5–10% → HDL +5–10%; also omega-3/eicosanoid modulation). PCSK9 (proprotein convertase subtilisin/kexin type 9; binds LDL-R → lysosomal degradation → elevated LDL; NF-κB target): phycocyanin NF-κB → PCSK9 transcription −10–20% → LDL-R density → LDL-C uptake +5–10%; modest LDL-C −5–10%.
Platelet Activation and Thrombotic Risk
Platelet activation (plaque rupture → collagen exposure → GP1b-IX-V/GPVI → Ca2+/TXA2/ADP amplification loop; TXA2 (thromboxane A2; COX-1 product in platelets; TP-receptor → Gq → IP3/DAG → Ca2+/PKC → dense granule (ADP/serotonin) + α-granule (fibrinogen/vWF/PDGF) release; arachidonic acid → TXA2 via COX-1/TXS)); fibrin formation → thrombus): spirulina reduces thrombotic risk through: (1) GLA → DGLA → TXA1 (weaker TXA2 congener; partial agonist at TP-receptor; net anti-thrombotic) via COX-1 substrate competition; (2) EPA → TXA3 (largely inactive; anti-thrombotic) vs. AA → TXA2 competition; (3) Omega-3 phospholipid membrane incorporation → platelet membrane fluidity changes → GP1b clustering reduced; (4) NO (eNOS spirulina → NO → sGC → cGMP → PKG → VASP Ser239 phosphorylation → platelet fibrinogen receptor GPIIb/IIIa conformational inhibition → platelet aggregation −15–25%). TXA2: −15–25% urinary 11-dehydroTXB2 (TXA2 metabolite).
Endothelial Adhesion Molecule and Plaque Stability
Atherosclerotic plaque stability (fibrous cap integrity; SMC content; macrophage/foam cell content; lipid core size; calcification; MMP-9 activity → fibrous cap thinning): spirulina contributes to plaque stabilisation: (1) ICAM-1/VCAM-1 −25–40% (NF-κB) → reduced monocyte recruitment → less foam cell accumulation in existing plaques; (2) MMP-9 −20–30% (NF-κB) → fibrous cap protection; (3) SIRT1 → p53 deacetylation → SMC apoptosis resistance → fibrous cap cell viability; (4) VCAM-1/E-selectin reduction → plaque monocyte recruitment attenuation. Carotid IMT (intima-media thickness; surrogate atherosclerosis progression): −0.03–0.07 mm at 16–24 weeks in hypertensive/MetS subjects in some RCTs.
Clinical Outcomes in Cardiovascular Risk
- oxLDL (plasma): −15–25%
- Plasma TG (fasting): −15–25%
- HDL-C: +5–10%
- LDL-C (modest reduction): −5–10%
- ICAM-1 (soluble; plasma): −20–30%
- Carotid IMT: −0.03–0.07 mm at 16–24 weeks
Dosing and Drug Interactions
Cardiovascular risk reduction: 5–10g daily for 12–24 weeks. Statins (HMG-CoA reductase inhibitors): Statins address LDL-C directly via PCSK9 upregulation; spirulina PCSK9 −10–20% + endothelial NF-κB mechanisms: complementary and non-overlapping. Spirulina may partially offset statin CoQ10 depletion (NQO1-CoQH2 recycling). PCSK9 inhibitors (evolocumab, alirocumab): Spirulina modest PCSK9 reduction complementary; minimal clinical relevance vs. >50% PCSK9 inhibitor blockade. Omega-3 supplements (EPA/DHA; 2–4g/day): Spirulina omega-3 precursors (GLA→DGLA; ALA→EPA) are complementary to preformed EPA/DHA; combined for TG >2 mmol/L. Aspirin: Aspirin irreversible COX-1 inhibition + spirulina GLA→DGLA TXA1 competition: additive anti-thrombotic; no interaction. Summary: oxLDL −15–25%, TG −15–25%, HDL +5–10%, IMT −0.03–0.07 mm; dosing 5–10g daily. NK concern: low.